Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity-Reference-Cited by-同舟云学术

Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity

Published:2023-07 Issue: Volume:93 Page:104663
ISSN:2352-3964
Container-title:eBioMedicine
language:en
Short-container-title:eBioMedicine

Author:

Hiemstra Ida H.,Santegoets Kim C.M.^ORCID,Janmaat Maarten L.^ORCID,De Goeij Bart E.C.G.,Ten Hagen Wessel,van Dooremalen Sanne,Boross Peter,van den Brakel Jeroen,Bosgra Sieto,Andringa Grietje,van Kessel-Welmers Berris,Verzijl Dennis^ORCID,Hibbert Richard G.,Frerichs Kristine A.,Mutis Tuna,van de Donk Niels W.C.J.,Ahmadi Tahamtan,Satijn David,Sasser A. Kate,Breij Esther C.W.

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference29 articles.

1. A novel platform for the potentiation of therapeutic antibodies based on antigen-dependent formation of IgG hexamers at the cell surface;de Jong;PLoS Biol,2016

2. Complement is activated by IgG hexamers assembled at the cell surface;Diebolder;Science,2014

3. CD38-Specific biparatopic heavy chain antibodies display potent complement-dependent cytotoxicity against multiple myeloma cells;Schutze;Front Immunol,2018

4. DuoHexaBody-CD37((R)), a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies;Oostindie;Blood Cancer J,2020

5. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma;Lin;Am J Clin Pathol,2004

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing Fc‐mediated effector functions of monoclonal antibodies: The example of HexaBodies;Immunological Reviews;2024-09-14

2. Complement‐targeted therapeutics: Are we there yet, or just getting started?;European Journal of Immunology;2024-09-12

3. Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas;International Journal of Molecular Sciences;2024-08-24

4. Anti-HER2 Cancer-Specific mAb, H2Mab-250-hG1, Possesses Higher Complement-Dependent Cytotoxicity than Trastuzumab;International Journal of Molecular Sciences;2024-08-01

5. CIMT 2024: Report on the 21st Annual Meeting of the Association for Cancer Immunotherapy;Human Vaccines & Immunotherapeutics;2024-07-23